CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	BLU-222 Sensitive: C2 – Inclusion Criteria BLU-222 Sensitive : C2	BLU-222 Sensitive: C2 – Inclusion Criteria BLU-222 Sensitive : C2
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	INX-315 Sensitive: C2 – Inclusion Criteria INX-315 Sensitive : C2	INX-315 Sensitive: C2 – Inclusion Criteria INX-315 Sensitive : C2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	PF-07104091 Sensitive: C2 – Inclusion Criteria PF-07104091 Sensitive : C2	PF-07104091 Sensitive: C2 – Inclusion Criteria PF-07104091 Sensitive : C2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	BLU-222 Sensitive: C3 – Early Trials BLU-222 Sensitive : C3	BLU-222 Sensitive: C3 – Early Trials BLU-222 Sensitive : C3
CCNE1 amplification	Breast Cancer	CCNE1 amplification	Breast Cancer	CDK2 inhibitor Sensitive: D – Preclinical CDK2 inhibitor Sensitive : D	CDK2 inhibitor Sensitive: D – Preclinical CDK2 inhibitor Sensitive : D
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	ribociclib + BLU-222 Sensitive: D – Preclinical ribociclib + BLU-222 Sensitive : D	ribociclib + BLU-222 Sensitive: D – Preclinical ribociclib + BLU-222 Sensitive : D
CCNE1 amplification	Gastric Cancer	CCNE1 amplification	Gastric Cancer	INX-315 Sensitive: D – Preclinical INX-315 Sensitive : D	INX-315 Sensitive: D – Preclinical INX-315 Sensitive : D
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib + BLU-222 Sensitive: D – Preclinical palbociclib + BLU-222 Sensitive : D	palbociclib + BLU-222 Sensitive: D – Preclinical palbociclib + BLU-222 Sensitive : D

CDK2 inhibitor

CDK2 inhibitor

Associations(8)

Associations
(8)